These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36194133)

  • 21. Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019.
    Yamamoto C; Taniguchi M; Furukawa K; Inaba T; Niiyama Y; Ide D; Mizutani S; Kuroda J; Tanino Y; Nishioka K; Watanabe Y; Takayama K; Nakaya T; Nukui Y
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
    Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
    Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
    Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
    Bouzidi HS; Driouich JS; Klitting R; Bernadin O; Piorkowski G; Amaral R; Fraisse L; Mowbray CE; Scandale I; Escudié F; Chatelain E; de Lamballerie X; Nougairède A; Touret F
    Antiviral Res; 2024 Feb; 222():105814. PubMed ID: 38272321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].
    Reina J; Iglesias C
    Rev Esp Quimioter; 2022 Jun; 35(3):236-240. PubMed ID: 35183067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases.
    Leonard RA; Rao VN; Bartlett A; Froggatt HM; Luftig MA; Heaton BE; Heaton NS
    J Virol; 2023 Aug; 97(8):e0059723. PubMed ID: 37578235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of
    Tong X; Keung W; Arnold LD; Stevens LJ; Pruijssers AJ; Kook S; Lopatin U; Denison M; Kwong AD
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0084023. PubMed ID: 37800975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.
    Sasi VM; Ullrich S; Ton J; Fry SE; Johansen-Leete J; Payne RJ; Nitsche C; Jackson CJ
    Biochemistry; 2022 Nov; 61(22):2495-2505. PubMed ID: 36326185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ensitrelvir as a potential treatment for COVID-19.
    McCarthy MW
    Expert Opin Pharmacother; 2022 Dec; 23(18):1995-1998. PubMed ID: 36350029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376.
    Ye G; Wang X; Tong X; Shi Y; Fu ZF; Peng G
    Viruses; 2020 Feb; 12(2):. PubMed ID: 32098094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease.
    Flynn JM; Huang QYJ; Zvornicanin SN; Schneider-Nachum G; Shaqra AM; Yilmaz NK; Moquin SA; Dovala D; Schiffer CA; Bolon DNA
    ACS Infect Dis; 2023 Jul; 9(7):1372-1386. PubMed ID: 37390404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19.
    Liu H; Iketani S; Zask A; Khanizeman N; Bednarova E; Forouhar F; Fowler B; Hong SJ; Mohri H; Nair MS; Huang Y; Tay NES; Lee S; Karan C; Resnick SJ; Quinn C; Li W; Shion H; Xia X; Daniels JD; Bartolo-Cruz M; Farina M; Rajbhandari P; Jurtschenko C; Lauber MA; McDonald T; Stokes ME; Hurst BL; Rovis T; Chavez A; Ho DD; Stockwell BR
    Nat Commun; 2022 Apr; 13(1):1891. PubMed ID: 35393402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir.
    Paciaroni A; Libera V; Ripanti F; Orecchini A; Petrillo C; Francisci D; Schiaroli E; Sabbatini S; Gidari A; Bianconi E; Macchiarulo A; Hussain R; Silvestrini L; Moretti P; Belhaj N; Vercelli M; Roque Y; Mariani P; Comez L; Spinozzi F
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.
    Fukao K; Nobori H; Kuroda T; Baba K; Matsumoto K; Tanaka Y; Tachibana Y; Kato T; Shishido T
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation.
    Bei ZC; Yu H; Wang H; Li Q; Wang B; Zhang D; Xu L; Zhao L; Dong S; Song Y
    Emerg Microbes Infect; 2023 Dec; 12(1):2211688. PubMed ID: 37144395
    [No Abstract]   [Full Text] [Related]  

  • 37. Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors.
    Bao HL; Tu G; Yue Q; Liu P; Zheng HL; Yao XJ
    Chem Biol Drug Des; 2023 Oct; 102(4):857-869. PubMed ID: 37563791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations.
    Westberg M; Su Y; Zou X; Huang P; Rustagi A; Garhyan J; Patel PB; Fernandez D; Wu Y; Hao C; Lo CW; Karim M; Ning L; Beck A; Saenkham-Huntsinger P; Tat V; Drelich A; Peng BH; Einav S; Tseng CK; Blish C; Lin MZ
    Sci Transl Med; 2024 Mar; 16(738):eadi0979. PubMed ID: 38478629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CL
    Xiong Y; Zhu GH; Zhang YN; Hu Q; Wang HN; Yu HN; Qin XY; Guan XQ; Xiang YW; Tang H; Ge GB
    Int J Biol Macromol; 2021 Sep; 187():976-987. PubMed ID: 34333006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
    Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
    Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.